Physician profile
Alexander Bakis
NPI 1366510083
$5,195.85
in general payments reported to CMS, 2019-2025
24 companies · $788 in 2025
The $788 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $355 · 2021: $1,039 · 2022: $1,052 · 2023: $574 · 2024: $656 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,047.47 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $512.41 | 2019-2025 | Linzess, Viberzi |
| Nestle Healthcare Nutrition INC. | $407.17 | 2020-2023 | |
| Amarin Pharma, INC. | $387.98 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $333.02 | 2019-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $321.44 | 2019-2024 | Camzyos, Eliquis |
| Amgen INC. | $274.08 | 2024-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $273.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Arbor Pharmaceuticals, INC. | $232.53 | 2019-2021 | |
| Horizon Therapeutics Plc | $217.56 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $180.23 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $174.05 | 2021-2022 | |
| Pfizer INC. | $173.53 | 2021-2025 | |
| Medtronic, INC. | $155.25 | 2022 | |
| Allergan, INC. | $141.82 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $63.04 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $60.93 | 2019 | |
| Ardelyx, INC. | $55.57 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $51.67 | 2021-2025 | Trelegy Ellipta |
| Endo Pharmaceuticals INC. | $40.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $34.85 | 2020-2024 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $20.16 | 2019 | |
| Scilex Pharmaceuticals INC. | $20.13 | 2024 | |
| Redhill Biopharma INC. | $17.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Bakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.